VitroGro now in powdered form
05 October, 2005 by Ruth BeranProtein chemists at Queensland University of Technology (QUT) have produced a new freeze-dried form of Brisbane-based Tissue Therapies' (ASX:TIS) wound-healing technology VitroGro.
Brumby wants therapeutic cloning ban lifted
30 September, 2005 by Ruth BeranVictorian treasurer and minister for innovation, John Brumby, has called on the federal government to lift its ban on somatic cell nuclear transfer (SCNT), otherwise known as therapeutic cloning.
Norwood Immunology granted six patents
29 September, 2005 by Ruth BeranMelbourne immune therapy developer Norwood Immunology (AIM:NIL) has been granted six patents in New Zealand, South Africa and Singapore relating to its technology in key areas such as cancer and infectious diseases.
Bird flu: threat to Australia 'unlikely'
27 September, 2005 by Graeme O'NeillAn Australian expert on influenza believes it is unlikely that migratory birds will carry Asia's lethal H5N1 'bird 'flu' strain to Australia.
Chemeq signs $1.4m sales order
23 September, 2005 by Ruth BeranPerth-based Chemeq (ASX:CMQ) has signed a new sales order for the shipment of CHEMEQ polymeric antimicrobial worth AUD$1.4 million over the next nine months.
Agenix aims to raise $9.85m
19 September, 2005 by Ruth BeranBrisbane-based Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) has lodged a prospectus for an underwritten non-renounceable rights issue to raise $9.85 million before costs.
Four unis to team on plant biotech project
15 September, 2005 by Graeme O'NeillFour Australian universities have made an unusual decision to form a 'virtual company', Meristomics, to commercialise discoveries from basic research in their jointly operated ARC Centre of Excellence for Integrative Legume Research (CILR).
Stem Cell Sciences signs licensing deal with Deltagen
06 September, 2005 by Ruth BeranStem Cell Sciences (AIM:STEM, SCS) has signed a licensing agreement with US-based drug discovery tools and services provider Deltagen for use of its patented internal ribosome entry sites (IRES) technology.
Researchers gear up for stem cell review process
31 August, 2005 by Graeme O'NeillIndividuals and groups opposed to stem cell research have dominated submissions to the Lockhart Legislative Review of Australia's stem cell legislation.
GroPep reports double profits
22 August, 2005 by Helen SchullerAdelaide-based GroPep (ASX:GRO) has recorded pre-tax profit of AUD$3.1 million for the year ending 30 June 2005, an increase of more than 200 per cent over the $1 million reported last year.
Stem Cell Sciences to commercialise neural technology
18 August, 2005 by Helen SchullerBioTech Capital (ASX:BTC) investee Stem Cell Sciences has been awarded an exclusive license to a new patented technology to derive and grow neural stem cells.
NeuroDiscovery closes IPO
12 August, 2005 by Helen SchullerPerth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) has closed its $1.5 million IPO and completed its acquisition of UK-based NeuroSolutions.
Solagran defends ASX query on cash position
09 August, 2005 by Helen SchullerBotanical therapeutics specialist Solagran (ASX:SLA) has defended its financial position, after receiving a 'please explain' from the Australian Stock Exchange.
Diosynth to manufacture Agenix' Thromboview
05 August, 2005 by Helen SchullerAgenix (ASX:AGX, NASDAQ:OTC:AGXLY) has signed a multi-million dollar contract with US company Diosynth Biotechnology to begin the process of manufacturing its ThromboView blood clot imaging product for phase III clinical trials and commercial sale.
Norwood Immunology patent granted for Russia
01 August, 2005 by Helen SchullerNorwood Immunology, a subsidiary of Norwood Abbey (ASX:NAL) has been granted a additional patent relating to its immunology technology for a number of Eurasian territories, including Russia.
